The meeting will be closed to the public in accordance with the provisions set forth in sections 552B(c)(4) and 552B(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Cancer Institute Special Emphasis Panel; Test to Predict Effectiveness of Docetaxel Treatment for Prostate Cancer.

**Date:** March 28, 2013.

**Time:** 8:00 a.m. to 5:00 p.m.

**Agenda:** To review and evaluate contract proposals.

**Place:** National Institutes of Health, Room 507, 6116 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call).

**Contact Person:** Michael B. Small, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Blvd., Room 8127, Bethesda, MD 20892–8328, 301–402–0996, smallm@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)


Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013–04850 Filed 3–1–13; 8:45 am]

**BILLING CODE 4140–01–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Substance Abuse and Mental Health Services Administration**

**Current List of Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies**

**AGENCY:** Substance Abuse and Mental Health Services Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Department of Health and Human Services (HHS) notifies Federal agencies of the Laboratories and Instrumented Initial Testing Facilities (IITF) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the Federal Register on April 11, 1988 (53 FR 11970), and subsequently revised in the Federal Register on June 9, 1994 (59 FR 29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 16644); November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); and on April 30, 2010 (75 FR 22809).

A notice listing all currently certified Laboratories and Instrumented Initial Testing Facilities (IITF) is published in the Federal Register during the first week of each month. If any Laboratory/ IITF’s certification is suspended or revoked, the Laboratory/IITF will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines. If any Laboratory/IITF has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end and will be omitted from the monthly listing thereafter.

This notice is also available on the Internet at http://www.workplace.samhsa.gov and http://www.drugfreeworkplace.gov.

**FOR FURTHER INFORMATION CONTACT:** Mrs. Giselle Hersh, Division of Workplace Programs, SAMHSA/CASF, Room 2–1042, One Choke Cherry Road, Rockville, Maryland 20857; 240–276–2600 (voice), 240–276–2610 (fax).

**SUPPLEMENTAL INFORMATION:** The Mandatory Guidelines were initially developed in accordance with Executive Order 12564 and section 503 of Public Law 100–71. The “Mandatory Guidelines for Federal Workplace Drug Testing Programs”, as amended in the revisions listed above, requires strict standards that Laboratories and Instrumented Initial Testing Facilities (IITF) must meet in order to conduct drug and specimen validity tests on urine specimens for Federal agencies. To become certified, an applicant Laboratory/IITF must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a Laboratory/IITF must participate in a quarterly performance testing program plus undergo periodic, on-site inspections.

Laboratories and Instrumented Initial Testing Facilities (IITF) in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A Laboratory/ IITF must have its letter of certification from HHS/NIDA (formerly: HHS/ NIDA) which attests that it has met minimum standards.

In accordance with the Mandatory Guidelines dated November 25, 2008 (73 FR 71858), the following Laboratories and Instrumented Initial Testing Facilities (IITF) meet the minimum standards to conduct drug and specimen validity tests on urine specimens:

**Instrumented Initial Testing Facilities (IITF)**

None.

**Laboratories**

ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414–328–7840/800–877–7016 (Formerly: Bayshore Clinical Laboratory)

ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624, 585–429–2264

Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, Memphis, TN 38118, 901–794–5770/888–290–1150

Aegis Analytical Laboratories, 345 Hill Ave., Nashville, TN 37210, 615–255–2400 (Formerly: Aegis Sciences Corporation, Aegis Analytical Laboratories, Inc.)

Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504–361–8989/800–433–3823 (Formerly: Kroll Laboratory Specialists, Inc., Laboratory Specialists, Inc.)

Alere Toxicology Services, 450 Southlake Blvd., Richmond, VA 23236, 804–378–9130 (Formerly: Kroll Laboratory Specialists, Inc., Scientific Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories, Inc.)

Baptist Medical Center—Toxicology Laboratory, 11401 I–30, Little Rock, AR 72209–7056, 501–202–2783 (Formerly: Forensic Toxicology Laboratory Baptist Medical Center)

Clinical Reference Lab, 8433 Quivira Road, Lenexa, KS 66215–2802, 800–445–6917

Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602, 229–671–2281

DrugScan, Inc., 200 Precision Road, Suite 200, Horsham, PA 19044, 800–235–4890

ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655, 662–236–2609

Fortes Laboratories, Inc., 25749 SW Canyon Creek Road, Suite 600, Wilsonville, OR 97070, 503–486–1023


Laboratory Corporation of America Holdings, 7207 N. Gessner Road,
Phamatech, Inc., 10151 Barnes Canyon
Pathology Associates Medical
Pacific Toxicology Laboratories, 9348
One Source Toxicology Laboratory, Inc.,
National Toxicology Laboratories, Inc.,
LabOne, Inc. d/b/a Quest Diagnostics,
Laboratory Corporation of America
Beecham Clinical Laboratories;
800–729–6432 (Formerly: SmithKline
Montreal Circle, Tucker, GA 30084,
5555
Road, San Diego, CA 92121, 858–643–
800–541–7891x7
Spokane, WA 99204, 509–755–8991/
Laboratories, 110 West Cliff Dr.,
Clinical Chemistry Division; UTMB
1213 Genoa-Red Bluff, Pasadena, TX
1100 California Ave., Bakersfield, CA
93304, 661–322–4250/800–350–3515
One Source Toxicology Laboratory, Inc.,
1213 Genoa-Red Bluff, Pasadena, TX
77504, 887–787–3774 (Formerly:
University of Texas Medical Branch,
Clinical Chemistry Division; UTMB
Pathology-Toxicology Laboratory)
Pacific Toxicology Laboratories, 9348
Denzel Ave., Chatsworth, CA 91311,
800–328–6942 (Formerly: Centinela
Hospital Airport Toxicology Laboratory)
Pathology Associates Medical
Laboratories, 110 West Cliff Dr.,
Phamatech, Inc., 10151 Barnes Canyon
Road, San Diego, CA 92121, 858–643–
5555
Quest Diagnostics Incorporated, 400
Egypt Road, Norristown, PA 19403,
610–631–4600/877–642–2216
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline Bio-
Science Laboratories)
Quest Diagnostics Incorporated, 8401
Fallbrook Ave., West Hills, CA 91304,
818–737–6370 (Formerly: SmithKline
Beecham Clinical Laboratories)
Redwood Toxicology Laboratory, 3650
Westwind Blvd., Santa Rosa, CA
95403, 707–570–4434
South Bend Medical Foundation, Inc.,
530 N. Lafayette Blvd., South Bend,
IN 46601, 574–234–4176 x1276
Southwest Laboratories, 4625 E. Cotton
Center Boulevard, Suite 177, Phoenix,
AZ 85040, 602–438–8507/800–279–
0027
STERLING Reference Laboratories, 2617
East 1 Street, Tacoma, Washington
98421, 800–442–0438
Toxicology & Drug Monitoring
Laboratory, University of Missouri
Hospital & Clinics, 301 Byrness Loop
70 West, Suite 208, Columbia, MO
65203, 573–882–1273
U.S. Army Forensic Toxicology Drug
Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755–
5235, 301–677–7085

*The Standards Council of Canada
(SCC) voted to end its Laboratory
Accreditation Program for Substance
Abuse (LAPSA) effective May 12, 1998.
Laboratories certified through that
program were accredited to conduct
forensic urine drug testing as required
by U.S. Department of Transportation
(DOT) regulations. As of that date, the
certification of those accredited
Canadian laboratories will continue
under DOT authority. The responsibility
for conducting quarterly performance
testing plus periodic on-site inspections
of those LAPSA-accredited laboratories
was transferred to the U.S. HHS, with the
HHS' NLCP contractor continuing to
have an active role in the performance
testing and laboratory inspection
processes. Other Canadian laboratories
wishing to be considered for the NLCP
may apply directly to the NLCP
contractor just as U.S. laboratories do.

Upon finding a Canadian laboratory to
be qualified, HHS will recommend that
DOT certify the laboratory (Federal
Register, July 16, 1996) as meeting the
minimum standards of the Mandatory
Guidelines published in the Federal
Register on April 30, 2010 (75 FR
22809). After receiving DOT
certification, the laboratory will be
included in the monthly list of HHS-
certified laboratories and participate in
the NLCP certification maintenance
program.

Janine Denis Cook,
Chemist, Division of Workplace Programs,
Center for Substance Abuse Prevention,
SAMHSA.

BILLING CODE 4160–20–P

DEPARTMENT OF HOMELAND SECURITY

[67 FR 20350, May 15, 2002]

HOMELAND SECURITY COUNCIL FOR
SCIENCE AND TECHNOLOGY

[44 FR 42107, October 31, 1979, as amended]

SUMMARY: The Homeland Security
Council for Science and Technology
will meet on March 21, 2013 in Washington, DC. The
meeting will be open to the public.

DATES: The HSSTAC will meet
Thursday, March 21, 2013 11:30 a.m.—
4:15 p.m. The meeting may close early
if the committee has completed its business.

ADDRESSES: The meeting will be held at the
Department of Homeland Security (DHS), Science and Technology
Directorate, 1120 Vermont Avenue NW.,
(Room 5–212), Washington, DC.

All visitors must pre-register in order
to gain entry to the building. To register,
please contact the person listed under
FOR FURTHER INFORMATION CONTACT,
below. Alternatively, you may register
via this Web site: http://www.dhs.gov/st-
hsstac. Select the link labeled “Click
Here to Register.” Please provide your
name, citizenship, organization (if any),
title (if any), email address (if any), and
telephone number.

For information on facilities or
services for individuals with disabilities
or to request special assistance at the
meeting, contact the person listed under
FOR FURTHER INFORMATION CONTACT,
below.

The materials that are provided to
committee members will also be
provided to the public. Materials that
are sent to committee members in
advance will be posted on the public
Web site below on or before March 21.
Materials that are provided to
committee members at the meeting
will be made available to public attendees,
and also posted to the public Web site
below as soon as possible after the
meeting. Check this Web site after